View Post

Mayo Breast Cancer Vaccine Could Be Available In Less Than A Decade

In Clinical Trials by Barbara Jacoby

By: Robin Seaton Jefferson From: forbes.com Researchers at Mayo Clinic in Jacksonville, Florida say a vaccine they have developed could be available within eight years that may not only stop the recurrence of breast and ovarian cancers, but prevent them from developing in the first place. “It is reasonable to say that we could have a vaccine within eight years …

View Post

New Evolution-Busting Drug Overcomes Resistance in Aggressive Breast Cancers

In Clinical Trials by Barbara Jacoby

By: Institute of Cancer Research From: scitechdaily.com A new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers, a new study has shown. Scientists at The Institute of Cancer Research, London, found that the drug could reinvigorate the response to chemotherapy in cancers that had become resistant, …

View Post

Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients

In In The News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com Health systems in the UK and US could cost-effectively screen all women with breast cancer for risky germline changes in a handful of breast or ovarian cancer genes, according to a new economic modeling analysis, identifying at-risk individuals who could benefit from additional imaging tests and cancer-reducing interventions. “[T]he costs of testing falling … can …

View Post

PARP Inhibitors Move Into First-Line for Ovarian Cancer

In Clinical Trials by Barbara Jacoby

By: Zosia Chustecka From: medscape.com The landscape of ovarian cancer treatment is changing rapidly, as PARP inhibitor (PARPi) drugs move into the first-line treatment space. Three new clinical trials with three different drugs show substantial benefit when a PARPi is used in patients with newly diagnosed ovarian cancer, leading experts to urge clinicians to use these drugs upfront in the …

View Post

FAK protein linked to chemotherapy resistance in ovarian cancer

In Clinical Trials by Barbara Jacoby

Source: University of California – San Diego From: sciencedaily.com Although the number of women being diagnosed and dying of ovarian cancer is declining, recurrence, drug resistance and mortality remain high for women with high-grade serous ovarian carcinoma, the most common form of epithelial ovarian cancer. A new study in the journal eLife by University of California San Diego School of …

View Post

Novel therapy studied for inherited breast cancer

In In The News by Barbara Jacoby

By: Will Sansom From: uthscsa.edu UT Health San Antonio researchers have discovered a novel way to kill cancers that are caused by an inherited mutation in BRCA1, the type of cancer for which actress Angelina Jolie had preventive double mastectomy and reconstructive surgery in 2013. “This represents a new treatment for inherited breast and ovarian cancer, which are higher in …

View Post

Researchers develop early detection test for ovarian cancer

In In The News by Barbara Jacoby

Source: Queen’s University Belfast Researchers from Queen’s University Belfast have developed a test that may be able to detect ovarian cancer up to two years earlier than current approaches. The researchers discovered that the presence of four proteins together, known as a biomarker panel, indicates the likelihood of Epithelial Ovarian Cancer (EOC), a type of ovarian cancer. Using these biomarkers …

View Post

USPSTF Formalizes Slightly Expanded BRCA Screening Recommendations

In In The News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com The US Preventive Services Task Force (USPSTF) has officially released its updated recommendations for BRCA-related cancer risk assessment, genetic counseling, and testing, maintaining the focus on family history that prompted reactions from patient advocate groups, testing labs, and others when the draft guidance was opened up to public commentary in February. The USPSTF — an …

View Post

Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

In Clinical Trials by Barbara Jacoby

From: PR Newswire – Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors – First-in-class investigational therapy using autologous CAR-T cells targeting advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (NASDAQ: XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to …

View Post

UT Southwestern Researchers find evidence a cancer drug may be extended to many more patients

In In The News by Barbara Jacoby

Source: UT Southwestern Medical Center From: PR Newswire A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating all cancers where the drugs are used, including ovarian and prostate cancers. The new study also revealed a potential biomarker indicating when …